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There are a limited number of paediatric antiretroviral drug options. Characterising the long
term safety and durability of different antiretrovirals in children is important to optimise man-
agement of HIV infected children and to determine the estimated need for alternative drugs
in paediatric regimens. We describe first-line antiretroviral therapy (ART) durability and rea-
sons for discontinuations in children at two South African ART programmes, where lopina-
vir/ritonavir has been recommended for children <3 years old since 2004, and abacavir
replaced stavudine as the preferred nucleoside reverse transcriptase inhibitor in 2010.
Methods
We included children (<16 years at ART initiation) who initiated3 antiretrovirals between
2004–2014 with1 follow-up visit on ART. We estimated the incidence of first antiretroviral
discontinuation using Kaplan-Meier analysis. We determined the reasons for antiretroviral
discontinuations using competing risks analysis. We used Cox regression to identify factors
associated with treatment-limiting toxicity.
Results
We included 3579 children with median follow-up duration of 41 months (IQR 14–72). At
ART initiation, median age was 44 months (IQR 13–89) and median CD4 percent was 15%
(IQR 9–21%). At three and five years on ART, 72% and 26% of children respectively
remained on their initial regimen. By five years on ART, the most common reasons for dis-
continuations were toxicity (32%), treatment failure (18%), treatment simplification (5%),
drug interactions (3%), and other or unspecified reasons (18%). The incidences of treatment
limiting toxicity were 50.6 (95% CI 46.2–55.4), 1.6 (0.5–4.8), 2.0 (1.2–3.3), and 1.3 (0.6–2.8)
per 1000 patient years for stavudine, abacavir, efavirenz and lopinavir/ritonavir respectively.
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Conclusions
While stavudine was associated with a high risk of treatment-limiting toxicity, abacavir, lopi-
navir/ritonavir and efavirenz were well-tolerated. This supports the World Health Organiza-
tion recommendation to replace stavudine with abacavir or zidovudine in paediatric first-line
ART regimens in order to improve paediatric first-line ART durability.
Introduction
World Health Organization (WHO) guidelines have progressively recommended earlier anti-
retroviral therapy (ART) initiation for children, with the most recent WHO recommendation
being immediate ART irrespective of CD4 count for all adults and children [1–4]. Children are
therefore increasingly initiating ART at younger ages. Since ART must be taken lifelong and
there are a limited number of paediatric antiretroviral options, knowing the long term safety
and durability of ART in children is important to optimise their management. In addition,
accurately forecasting future need for different antiretrovirals in children is important consid-
ering the challenges of ensuring adequate supply of appropriate pediatric antiretroviral formu-
lations given the small and diminishing size of the pediatric epidemic relative to the adult
epidemic. Knowledge of durability of currently used regimens such as abacavir and lopinavir-
ritonavir is therefore vital.
In 2010 the WHO advised against the use of stavudine due to its long term toxicity, and rec-
ommended the use of either abacavir or zidovudine instead [4]. In 2013 WHO recommended
lopinavir/ritonavir for first-line ART in all children less than three years old due to its superior
virologic suppression [5]. The limited data on ART modifications in children from resource-
limited countries suggest that fewer treatment modifications for any reason tend to occur in
resource-limited settings, where the number of alternative drugs is limited [6–8]. Notwith-
standing, there are very few studies describing the durability of the currently recommended
abacavir- or lopinavir/ritonavir-containing first-line paediatric ART regimens in routine care
[9, 10].
In South Africa, lopinavir/ritonavir has been part of recommended first-line ART for all
children less than three years old since 2004, and abacavir has been the preferred nucleoside
reverse transcriptase inhibitor since 2010 [11, 12]. A study in South African adults showed that
the incidence of antiretroviral substitutions decreased after stavudine was replaced with teno-
fovir as part of the preferred first-line regimen, [13] but it is unknown whether replacing stavu-
dine with abacavir had a similar effect on first-line ART regimen durability in paediatric
cohorts.
We describe ART regimen durability and reasons for discontinuation of first-line antiretro-
virals in children at two South African ART programmes from 2004–2014 covering the periods
both before and after the replacement of stavudine with abacavir in first-line paediatric ART.
Methods
Study setting and population
We included all eligible patients from the Khayelitsha HIV Treatment Programme, which
comprises three primary care clinics in Cape Town, South Africa, and from the HIV clinics at
Rahima Moosa Mother and Child Hospital (RMMCH) clinic, a tertiary hospital dedicated
to mother and child clinical care in Johannesburg, South Africa. Both sites provide HIV
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treatment services according to national guidelines and prospectively collect routine clinical
data electronically. We included treatment-naïve children less than 16 years old who initiated
ART with at least three antiretrovirals, between January 2004 and October 2013 (Khayelitsha)
or March 2014 (RMMCH), and had at least one follow-up visit.
Guidelines for ART initiation and treatment
South African national guideline ART eligibility and first-line regimen recommendations
changed over the study period (S1 and S2 Tables) [11, 12, 14, 15]. Briefly, in 2004, ART eligibil-
ity depended on CD4 percent/count values or WHO clinical stage [11]. By 2013, ART was
recommended for all children less than five years old, regardless of CD4 percent/count [14].
Before 2007, the recommended first-line ART regimens comprised stavudine and lamivudine,
with efavirenz in children older than three years; lopinavir/ritonavir in those aged six months
to three years; or ritonavir in those younger than six months [11, 15]. In 2007, lopinavir/rito-
navir was recommended instead of ritonavir in children less than six months old [15]. From 1
April 2010, abacavir was recommended instead of stavudine, and children were electively
changed to abacavir to prevent stavudine toxicity [12].
Data management and statistical analysis
Data were captured electronically at the sites, and combined using a standard data transfer for-
mat. We looked for inconsistencies and possible errors, which were corrected by the sites to
ensure completeness of ART prescription data. We used Stata 13.0 for data management and
analysis.
We estimated the incidences of stavudine, abacavir, efavirenz and lopinavir/ritonavir dis-
continuations using Kaplan-Meier analyses. We determined the reasons for antiretroviral dis-
continuations using competing risks analysis. We explored associations with treatment-
limiting toxicity using Cox regression. We included sex and weight-for-age z-score at ART ini-
tiation in the model a priori. We included age as a binary variable (<36 and36 months)
because of differing ART recommendations for those<36 months and36 months old.
We censored patients at the first of: death, transfer out, loss to follow-up, database closure,
or five years of follow-up. We considered patients lost to follow up if they had no visit for nine
months before database closure and censored them at their last visit date. We did not consider
treatment interruptions of less than two months to be a treatment discontinuation, unless the
reason for the interruption was documented as toxicity. Treatment failure included virological,
clinical, or immunological failure as defined by the treating physician using national guide-
lines. We defined treatment-limiting toxicity as the discontinuation of at least one antiretrovi-
ral with the reason for discontinuation documented as toxicity by the treating clinician.
Due to the 2010 guideline change that encouraged clinicians to change stavudine to abaca-
vir to prevent toxicity, it is possible that a proportion of stavudine discontinuations after this
date were actually pre-emptive to prevent toxicity rather than due to toxicity. We therefore
performed a sensitivity analysis that censored patient follow-up on 01 April 2010 and excluded
stavudine discontinuations that occurred after 01 April 2010.
Ethics
Data were anonymised to ensure patient confidentiality. The University of Cape Town and
University of the Witwatersrand Human Research Ethics Committees approved data collec-
tion and analysis. The study protocol was also reviewed and cleared as human subjects’
research by the U.S. Centers for Disease Control and Prevention (CDC).
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Results
Study cohort
We included 3 579 children with median follow-up of 41 months (IQR 14.1 to 71.8) (Table 1).
Four percent (142/3 579) of included children died, 75% (107/142) in the first year of ART.
Nineteen percent (662/3 579) of children were lost to follow up and 18% (648/3579) were
transferred to another facility. Rates of loss to follow up were similar at both sites. The propor-
tion of children who initiated ART before 12 months of age increased from 6% in 2004 to 29%
(49/170) in 2013. The most common first-line regimen was lamivudine and stavudine with
either efavirenz in children older than years (61%, 1199/1954)) or lopinavir/ritonavir in chil-
dren younger than three years (52%, 842/1625)).
Antiretroviral discontinuations
Thirty percent (1 071/3 579) of children had an antiretroviral discontinuation. The reason for
antiretroviral discontinuation was unknown in 58 (5%) children (13% at Khayelitsha and 2%
at Rahima Moosa). The overall incidence of first antiretroviral discontinuation was 85.9 per
1000 patient years (py) (95% confidence interval (CI) 80.2 to 92.0). After one, three and five
Table 1. Characteristics of children initiated on antiretroviral treatment (N = 3579).
Characteristics at ART initiation Ne All children N = 3579 Rahima Moosa N = 2464 Khayelitsha N = 1115
Median (IQR) Median (IQR) Median (IQR)
Age (months) 3579 43.5 (13.4–89.2) 43.4 (12.4–91.0) 43.8 (15.2–86.1)
CD4 percent (%) 1993 15 (9–21) 14 (8–20) 17 (11–24)
CD4 count (cells/mm3) 2192 468 (223–852) 436 (211–791) 536 (252–980)
Viral load (log10 copies) 1840 5.3 (4.5–6.0) 5.4 (4.7–6.5) 4.9 (4.0–5.7)
Weight-for age z score 2379 -1.5 (-2.5 to -0.5) -1.8 (-3.0 to -0.8) -0.9 (-1.8 to -0.1)
n (%) n (%) n (%)
Male gender 3577 1787 (50%) 1257 (51%) 530 (48%)
WHO clinical stage 3 or 4 2315 1628 (70%) 865 (70%) 763 (71%)
Severe immunosuppressiona 1845 1221 (66%) 947 (70%) 274 (55%)
Severe anaemia at ART initiationb 879 30 (3%) 30 (4%) 0 0
ART regimenc: 3579
NRTI Stavudine 2363 (66%) 1667 (68%) 696 (62%)
Abacavir 1040 (29%) 740 (30%) 300 (27%)
Zidovudine 161 (4%) 51 (2%) 110 (10%)
Tenofovir 15 (0.4%) 6 (0.2%) 9 (0.8)%)
PI or NNRTId Efavirenz 1849 (52%) 1356 (55%) 493 (44%)
Nevirapine 153 (4%) 42 (2%) 111 (10%)
Lopinavir/ritonovir 1522 (43%) 1034 (42%) 488 (44%)
Ritonavir alone 54 (2%) 31 (1%) 23 (2%)
a. Severe immunosuppression defined according to WHO 2006 criteria.
b. Severe anaemia defined as a haemoglobin of <7g/dL.
c. Most of the regimens were in the form NRTI+lamivudine+NNRTI/PI. Two children received emtricitabine instead of lamivudine. Percentages might not
add up to 100% due to rounding off.
d. Unspecified in one case.
e. Some variables were not measured in all children
ART: antiretroviral treatment. IQR: interquartile range. NRTI: nucleoside reverse transcriptase inhibitor. NNRTI: non-nucleoside reverse transcriptase
inhibitor. PI: protease inhibitor. WHO: World Health Organization
doi:10.1371/journal.pone.0169762.t001
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years 95%, 72% and 26% of children respectively remained on their initial first-line regimen
(Fig 1). In the first two years on ART, the rates of discontinuations for treatment failure and
for toxicity were similar, but toxicity was the most common reason for drug discontinuations
from three years onwards, with a cumulative incidence of 7% and 23% at three and five years
respectively. The drug most frequently discontinued was stavudine, with an incidence of 87
per 1 000 py (95% CI 81.1 to 92.8). In contrast, incidence of abacavir discontinuation was 30
per 1 000 patient years (95% CI 23.3 to 39.4). Drug-specific reasons for antiretroviral discon-
tinuations are shown in S3 Table.
Treatment-limiting toxicity
The overall rate of treatment-limiting toxicity was 13.4 per 1 000 py (95% CI 11.3 to 16.0). The
incidence of treatment limiting toxicity was 50.6 (95% CI 46.2 to 55.4) per 1 000 patient years
Fig 1. Proportion of children remaining on initial first-line antiretroviral regimen and reasons for
regimen change over 5 years of follow-up.
doi:10.1371/journal.pone.0169762.g001
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for stavudine, and 1.6 (95% CI 0.5 to 4.8), 2.0 (95% CI 1.2 to 3.3), and 1.3 (95% CI 0.6 to 2.8)
per 1 000 patient years for abacavir, efavirenz and lopinavir/ritonavir respectively. Lipodystro-
phy accounted for 95% (463/483) of treatment-limiting toxicities (450 due to stavudine and
seven due to efavirenz). Other causes of treatment-limiting toxicity included: hyperlactataemia
in five patients on stavudine; hypersensitivity reaction in two patients on abacavir; and neuro-
logical symptoms in one patient on efavirenz.
Results from adjusted cox-regression showed that children on stavudine were 30.8 times
more likely to experience treatment-limiting toxicity compared with children on abacavir
(95% CI: 4.3 to 220.2). Older age (36 months compared with<36 months) and site were also
significant predictors of treatment-limiting toxicity (Table 2).
Sensitivity analysis
More than two-thirds (68%, 571/841) of stavudine discontinuations occurred after 01 April
2010. In the sensitivity analysis that excluded stavudine discontinuations and follow-up after
01 April 2010, durability of first-line therapy at five years on ART increased from 26% to 52%;
and the adjusted hazard ratio for treatment-limiting toxicity for children on stavudine com-
pared with children on abacavir decreased from 30.8 to 9.9 (95% CI 1.4 to 71.8, adjusted for
age, site, sex and baseline weight-for-age z-score).
Discussion
In our cohort of 3 579 South African children, 28% and 74% of children had a first-line regi-
men discontinuation by three and five years on treatment respectively. The most common
reason for discontinuation was toxicity (13%) followed by treatment failure (7%). Receiving
stavudine and age over three years were associated with a higher risk of treatment-limiting
toxicity.
Our study is one of the first to examine regimen durability and treatment-limiting toxicity
after the replacement of stavudine with abacavir in first-line ART. In contrast to our findings,
treatment failure was a more common reason for antiretroviral discontinuation than toxicity
in other South African studies conducted before 2010. Reddi et al. [8] reported that 4.6% and
1.3% of discontinuations were due to treatment failure and toxicity respectively after a median
follow up of eight months, and Kampiire et al [16] reported that 6.7% and 3.1% of discontinua-
tions were due to treatment failure and toxicity respectively by three years on ART. This prob-
ably reflects the fact that without access to abacavir, clinicians were largely unable to switch
patients off of stavudine, even if they experienced toxicity. Although our study may over-
Table 2. Predictors of discontinuations due to toxicity using cox-proportional hazards regression among children followed up until 5 years
(n = 3579).
Variable Unadjusted HR (95% CI) P value Adjusteda HR (95% CI) P value
Site Khayelitsha (N = 1115) 1 1
Rahima Moosa (N = 2464) 2.5 (1.9 to 3.3) <0.001 2.8 (2.0 to 3.8) <0.001
Age (months) <36 (N = 1625) 1 1
36 (N = 1954) 1.7 (1.4 to 2.2) <0.001 1.80 (1.4 to 2.4) <0.001
NRTI Abacavir (N = 1043) 1 1
Stavudine (N = 2363) 17.0 (5.4 to 53.0) <0.001 30.8 (4.3 to 220.2) 0.001
Another NRTI (N = 1730) 0.8 (0.1 to 7.3) 0.8 4.7 (0.3 to 75.4) 0.279
a. Adjusted for sex and baseline weight-for-age z-score.
CI: confidence interval. HR: hazard ratio. NRTI: nucleoside reverse transcriptase inhibitor.
doi:10.1371/journal.pone.0169762.t002
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estimate stavudine toxicity as some patients were probably switched off of stavudine to prevent
toxicity, rather than because of toxicity itself, it is clear that introduction of abacavir-based
first-line regimens significantly reduced treatment-limiting toxicity. Only two patients experi-
enced abacavir hypersensitivity reaction in our study. The incidence of abacavir hypersensitiv-
ity reaction in children is lower than in adults [9, 17], and African descent reduces the risk
further [10, 18].
Our study shows that lopinavir/ritonavir and efavirenz were relatively well-tolerated with
incidences of treatment-limiting toxicity of 1.3 (95% CI 0.6 to 2.8) and 2.0 (95% CI 1.2 to 3.3)
per 1 000 patient years respectively. In contrast, studies conducted in Rwanda, Uganda and
India, where were most patients were on nevirapine-based ART, reported overall probabilities
of treatment-limiting toxicities of 8.3% [19], 19% [20], and 25.4% [21] respectively.
In our study, in addition to ART regimen (being on stavudine versus abacavir) older age
and site were independent predictors of treatment-limiting toxicity. It is unclear why older
children are more likely to experience treatment-limiting toxicity. The majority of children
36 months receive efavirenz while children <36 months receive lopinavir/ritonavir and, due
to these age-based regimens, we could not adjust for both age and efavirenz versus lopinavir/
ritonavir in the models. Consequently, we cannot exclude the possibility that efavirenz and not
older age is a risk factor for a treatment-limiting toxicity. Older children are more able to ver-
balize when they experience toxicity compared to younger children which may be important
especially for neuropsychiatric toxicity. In addition, lipodystrophy, the most common toxicity,
might be easier to diagnose in older children. Similarly, only three patients reported stavu-
dine-related peripheral neuropathy. The low incidence of peripheral neuropathy relative to
adult patients is consistent with previous studies, and might be due to both lower incidence
and difficulty diagnosing peripheral neuropathy in children [20, 22].
After adjusting for age, concomitant antiretrovirals, sex, and weight-for-age z-score, chil-
dren at Rahima Moosa Mother and Child Hospital were 2.8 times as likely as those at Khayelit-
sha clinic to experience a toxicity-related drug discontinuation. Children at Rahima Moosa
had lower average CD4 counts and a higher proportion of severe immune suppression than
those at Khayelitsha, which might have increased their risk for drug toxicity. In addition, clini-
cians at Rahima Moosa, a tertiary hospital, were probably more likely to have immediate access
to monitoring blood results and alternative antiretrovirals. They were also more likely to be
paediatricians, who were probably more confident in recognising adverse drug reactions and
switching children off of antiretrovirals than the primary care doctors and nurses at Khayelit-
sha clinics. The percentage of missing reasons for drug discontinuations was higher at Khaye-
litsha than at Rahima Moosa, so it is also possible that the effect of site on toxicity-related drug
discontinuations might be overestimated.
Data were collected from routine clinic practice and we relied on the treating clinicians’
diagnoses of toxicity with likely discrepancies across sites and between clinicians. Also, our
study focuses on treatment discontinuations relatively early in the course of ART as we
assessed only the first discontinuation of a drug. Treatment-limiting toxicities could also have
been under-estimated due to loss to follow-up, if children were lost to follow-up due to toxic-
ity. Nevertheless, our study is a large paediatric longitudinal study with long follow-up. It
spanned the periods before and after a drug protocol change occurred in South Africa, substi-
tution of stavudine with abacavir, which enabled us to describe abacavir durability. The
cohorts in this study are representative of clinic and hospital settings in South Africa and the
inclusion of both settings provides a better picture of treatment-limiting toxicity than if only
one setting were included. However, the generalisability to other African countries will depend
on drug regimens used, availability of alternative drugs and whether clinical monitoring is
comparable to our setting.
First-line antiretroviral discontinuations in children
PLOS ONE | DOI:10.1371/journal.pone.0169762 February 13, 2017 7 / 9
Conclusions
Durability of first-line ART was relatively high in our study. The introduction of abacavir
reduced treatment-limiting toxicity in comparison to stavudine, and the incidence of treat-
ment-limiting toxicity for patients on lopinavir/ritonavir or efavirenz was low. Nevertheless,
ongoing monitoring of the durability of first-line ART is required to accurately predict need
for alternative drug options in children as infants and children start ART earlier, availability of
alternative drugs and formulations increases, and children survive on ART into adolescence
and adulthood.
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